BRISTOL-MYERS SQUIBB COMPANY Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax of $13.00 million for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-10-25.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesBeforeTax · last filed 2018-10-25
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for the quarter ending 2018-09-30 was $13.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for the quarter ending 2018-06-30 was -$13.00M, a 230.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for the quarter ending 2018-03-31 was -$20.00M, a 190.91% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for the quarter ending 2017-12-31 was -$30.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for fiscal 2017 was -$19.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for fiscal 2016 was -$12.00M, a 109.23% decline from fiscal 2015.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for fiscal 2015 was $130.00M, a 217.07% increase from fiscal 2014.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), reclassification adjustment from aoci on derivatives, before tax for fiscal 2014 was $41.00M, a 26.79% decline from fiscal 2013.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax 3 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax 6 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax 9 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax 12 month |
|---|---|---|---|---|
| 2018-09-30 | $13.00M 10-Q · filed 2018-10-25 | $0.00 derived: sum of 2 quarters · filed 2018-10-25 | -$20.00M 10-Q · filed 2018-10-25 | -$50.00M derived: sum of 4 quarters · filed 2018-10-25 |
| 2018-06-30 | -$13.00M 10-Q · filed 2018-07-26 | -$33.00M 10-Q · filed 2018-07-26 | -$63.00M derived: sum of 3 quarters · filed 2018-07-26 | -$84.00M derived: sum of 4 quarters · filed 2018-10-25 |
| 2018-03-31 | -$20.00M 10-Q · filed 2018-04-26 | -$50.00M derived: sum of 2 quarters · filed 2018-04-26 | -$71.00M derived: sum of 3 quarters · filed 2018-10-25 | -$61.00M derived: sum of 4 quarters · filed 2018-10-25 |
| 2017-12-31 | -$30.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | -$51.00M derived: sum of 2 quarters · filed 2018-10-25 | -$41.00M derived: sum of 3 quarters · filed 2018-10-25 | -$19.00M 10-K · filed 2018-02-13 |
| 2017-09-30 | -$21.00M 10-Q · filed 2018-10-25 | -$11.00M derived: sum of 2 quarters · filed 2018-10-25 | $11.00M 10-Q · filed 2018-10-25 | $11.00M derived: sum of 4 quarters · filed 2018-10-25 |
| 2017-06-30 | $10.00M 10-Q · filed 2018-07-26 | $32.00M 10-Q · filed 2018-07-26 | $32.00M derived: sum of 3 quarters · filed 2018-07-26 | $11.00M derived: sum of 4 quarters · filed 2018-07-26 |
| 2017-03-31 | $22.00M 10-Q · filed 2018-04-26 | $22.00M derived: sum of 2 quarters · filed 2018-04-26 | $1.00M derived: sum of 3 quarters · filed 2018-04-26 | $6.00M derived: sum of 4 quarters · filed 2018-04-26 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | -$21.00M derived: sum of 2 quarters · filed 2018-02-13 | -$16.00M derived: sum of 3 quarters · filed 2018-02-13 | -$12.00M 10-K · filed 2018-02-13 |
| 2016-09-30 | -$21.00M 10-Q · filed 2017-10-26 | -$16.00M derived: sum of 2 quarters · filed 2017-10-26 | -$12.00M 10-Q · filed 2017-10-26 | $16.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | $5.00M 10-Q · filed 2017-07-27 | $9.00M 10-Q · filed 2017-07-27 | $37.00M derived: sum of 3 quarters · filed 2018-02-13 | $76.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | $4.00M 10-Q · filed 2017-04-27 | $32.00M derived: sum of 2 quarters · filed 2018-02-13 | $71.00M derived: sum of 3 quarters · filed 2018-02-13 | $107.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | $28.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $67.00M derived: sum of 2 quarters · filed 2018-02-13 | $103.00M derived: sum of 3 quarters · filed 2018-02-13 | $130.00M 10-K · filed 2018-02-13 |
| 2015-09-30 | $39.00M 10-Q · filed 2016-10-27 | $75.00M derived: sum of 2 quarters · filed 2016-10-27 | $102.00M 10-Q · filed 2016-10-27 | $135.00M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-06-30 | $36.00M 10-Q · filed 2016-07-28 | $63.00M 10-Q · filed 2016-07-28 | $96.00M derived: sum of 3 quarters · filed 2017-02-21 | $109.00M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-03-31 | $27.00M 10-Q · filed 2016-04-28 | $60.00M derived: sum of 2 quarters · filed 2017-02-21 | $73.00M derived: sum of 3 quarters · filed 2017-02-21 | $66.00M derived: sum of 4 quarters · filed 2017-02-21 |
| 2014-12-31 | $33.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $46.00M derived: sum of 2 quarters · filed 2017-02-21 | $39.00M derived: sum of 3 quarters · filed 2017-02-21 | $41.00M 10-K · filed 2017-02-21 |
| 2014-09-30 | $13.00M 10-Q · filed 2015-10-27 | $6.00M derived: sum of 2 quarters · filed 2015-10-27 | $8.00M 10-Q · filed 2015-10-27 | $17.00M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | -$7.00M 10-Q · filed 2015-07-23 | -$5.00M 10-Q · filed 2015-07-23 | $4.00M derived: sum of 3 quarters · filed 2016-02-12 | $7.00M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | $2.00M 10-Q · filed 2015-04-28 | $11.00M derived: sum of 2 quarters · filed 2016-02-12 | $14.00M derived: sum of 3 quarters · filed 2016-02-12 | $48.00M derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | $9.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $12.00M derived: sum of 2 quarters · filed 2016-02-12 | $46.00M derived: sum of 3 quarters · filed 2016-02-12 | $56.00M 10-K · filed 2016-02-12 |
| 2013-09-30 | $3.00M 10-Q · filed 2014-10-24 | $37.00M derived: sum of 2 quarters · filed 2014-10-24 | $47.00M 10-Q · filed 2014-10-24 | $60.00M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | $34.00M 10-Q · filed 2014-07-24 | $44.00M 10-Q · filed 2014-07-24 | $57.00M derived: sum of 3 quarters · filed 2015-02-13 | $79.00M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | $10.00M 10-Q · filed 2014-04-29 | $23.00M derived: sum of 2 quarters · filed 2015-02-13 | $45.00M derived: sum of 3 quarters · filed 2015-02-13 | |
| 2012-12-31 | $13.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $35.00M derived: sum of 2 quarters · filed 2015-02-13 | $56.00M 10-K · filed 2015-02-13 | |
| 2012-09-30 | $22.00M 10-Q · filed 2013-10-23 | $43.00M 10-Q · filed 2013-10-23 | ||
| 2011-12-31 | -$52.00M 10-K · filed 2014-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |